联系我们

论文查询结果	返回搜索

论文编号：	7926
作者编号：	2120132581
上传时间：	2015/12/8 18:19:54
中文题目：	CL医药公司并购战略研究
英文题目：	The research of CL pharmaceutical company mergers and acquisitions strategy
指导老师：	武立东
中文关键字：	并购战略;横向并购,纵向并购;同心多元化;战略协同
英文关键字：	Merger and acquisition strategy; horizontal merger and acquisition, vertical merger and acquisition; concentric diversification; strategic cooperation
中文摘要：	企业并购，是国内外企业在发展过程中一项重要的管理决策活动。通过并购，企业可以更有效地利用相关资源优势，进一步巩固自身在市场、研发、生产、技术等方面优势，从而为长期可持续发展提供更坚实基础。近年来，随着国内经济结构转型升级步伐加快，我国医药行业内的并购活动也更为频繁。如何制定符合企业发展实际与管理实际的并购战略，成为大部分医药企业管理层关注的主要问题之一。本文以CL医药企业为研究对象，结合战略管理、企业并购等相关理论，采用案例分析等方法，具体研究了医药企业的并购战略相关问题。经对CL医药公司内外部并购环境进行分析，发现CL公司存在较好的外部发展机遇，如中国逐步进入老龄化社会，糖尿病、老年痴呆疾病和肾病等群体人数持续增加；新环保法实施提高了对空气污染治理的重视程度，这为公司发展提供了较好的机遇；同时，公司因在研发、技术、质量控制等方面拥有相关优势，这为公司及时把握市场机遇奠定了基础。随后，本文综合内外部分析、SWOT分析结果，认为未来CL医药公司应将并购战略定位于多元化并购战略，不断延伸公司的产业链条，丰富公司的产品体系，将有助于降低公司未来发展过程中的运营风险，增强CL医药公司可持续发展动力；具体地，一是在以抗病毒药物领域基础上。以糖尿病、老年痴呆疾病和肾病药物领域等相关药物产品为主要方向，横向并购；二是以汽车尾气净化产品相关产品为方向，进行纵向并购。此外，分析还认为，在进行横向并购时，CL公司应采用“同心多元化”并购策略；在进行纵向并购业务时，采取“上下并进”的并购策略。最后，为确保CL医药公司切实落实相关并购战略，本文从战略协同、文化先行入手,通过组织保障和文化先行、财务保障、后期整合、并购风险控制等方面采取相应的保障措施。本文研究对国内相关医药企业进行并购战略制定具有一定的现实参考价值。
英文摘要：	Mergers and acquisitions, it is very important in the domestic and foreign enterprises in the development process of the management decision-making activities. Through mergers and acquisitions, companies can more effectively use the related resources advantages, to further consolidate itself in the market, research and development, production, technical advantages, which provide more solid foundation for the long-term sustainable development. In recent years, with the acceleration of transformation and upgrading of domestic economic structure, China's pharmaceutical industry mergers and acquisitions are also more frequent. How to develop the accords with the practice of enterprise development and management of actual m&a strategy,become one of the most major concern in pharmaceutical to enterprise management. In this paper, we take CL pharmaceutical enterprises as the research object, combining the theory of strategic management, mergers and acquisitions, etc, the methods of case analysis, the concrete research of pharmaceutical enterprise merger and acquisition strategy related issues. Through the analysis of CL pharmaceutical companies internal and external environment, found CL company is a better external development opportunities, such as China gradually into aging society, the number of groups such as Diabetes, Alzheimer's disease and nephropathy disease continues to increase; New environmental law implementation improved the degree of attention to the air pollution control, it provides a good opportunity for the company development; At the same time, the company in research and development, technology, quality control and so on has the advantage, the timely grasp the market opportunity for the company laid a solid foundation. Then, in this paper, the results based on the analysis of internal and external, the SWOT analysis, think the future CL pharmaceutical company merger and acquisition strategy should be aimed at diversification m&a strategy, continuously extend the industrial chain, enrich the company's products system, will help to reduce the operational risk in the process of the company's future development, enhance CL pharmaceutical companies sustainable development power; Specifically, one is diabetes and other related products as the main direction, horizontal mergers and acquisitions, Second is automobile exhaust purification product related products for the direction, vertical mergers and acquisitions. In addition, the analysis also believes that in the horizontal mergers and acquisitions, CL company shall adopt the concentric diversification m&a strategy; In the vertical mergers and acquisitions, take "hand up and down" m&a strategy. Finally, in order to ensure the CL pharmaceutical companies to implement related m&a strategy, this article from the organization's security and culture first, financial security, integration, mergers and acquisitions late put forward the corresponding safeguard measures of risk control, etc. In this paper, we study on related domestic pharmaceutical enterprises mergers and acquisitions strategy development has a certain practical reference value.
查看全文：	预览  下载(下载需要进行登录)